Holen Sie sich die Stockscreener-App
2.025
1.22%
-0.025
Handel nachbörslich:
1.99
-0.035
-1.73%
Schlusskurs vom Vortag:
$2.05
Offen:
$2.04
24-Stunden-Volumen:
10,398
Relative Volume:
0.38
Marktkapitalisierung:
$22.01M
Einnahmen:
$56.60M
Nettoeinkommen (Verlust:
$-34.12M
KGV:
-0.4417
EPS:
-4.5844
Netto-Cashflow:
$-1.36M
1W Leistung:
-2.17%
1M Leistung:
-4.48%
6M Leistung:
-20.90%
1J Leistung:
-19.32%
1-Tages-Spanne:
$2.02
$2.0705
1-Wochen-Bereich:
$2.02
$2.15
52-Wochen-Spanne:
$1.80
$3.065
Aytu Biopharma Inc Stock (AYTU) Company Profile
Firmenname
Aytu Biopharma Inc
Sektor
Telefon
(720) 437-6580
Adresse
7900 E. UNION AVENUE, DENVER
Compare AYTU vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.025 | 22.01M | 56.60M | -34.12M | -1.36M | -4.5844 |
TAK
Takeda Pharmaceutical Co Adr
|
18.73 | 59.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.10 | 47.93B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.32 | 40.99B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
74.81 | 30.91B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.16 | 23.55B | 3.17B | 1.29B | 1.01B | 27.09 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-01 | Eingeleitet | Lake Street | Buy |
| 2025-06-30 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2021-03-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-05-29 | Eingeleitet | H.C. Wainwright | Buy |
Aytu Biopharma Inc Aktie (AYTU) Neueste Nachrichten
Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy? - Zacks Investment Research
Aytu BioPharma (NasdaqCM:AYTU) Stock Forecast & Analyst Predictions - Simply Wall Street
Latigo Biotherapeutics, Inc. Common Stock (LTGO) Earnings Reports & Dates - FXEmpire
AYTU|Aytu Biopharma Inc|Price:2.230|Chg%:+0.105 - TradingKey
Aytu BioPharma Narrows Fiscal 2026 Loss to $14.3 Million as EXXUA Debuts - Minichart
Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates - Zacks Investment Research
EXXUA prescriptions jump as Aytu BioPharma (AYTU) posts Q4 and full-year results - Stock Titan
A depression drug generated $3.9 million in its first full quarter - Stock Titan
When Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Turn A Profit? - simplywall.st
AYTU Q2 2026 Earnings: Loss Per Share Misses by 1.88% as Stock Holds UpDividend Cut Risk - vinanet.vn
AYTU | AYTU BioPharma, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Aytu (AYTU) Q2 2026 Earnings: EPS Misses Its Estimate; Closing Move: The Market Reaction Is Muted in the Current UpdatePerformance Review - vinanet.vn
Aytu BioPharma (AYTU) investor and foundation each report 4.99% beneficial stake - Stock Titan
Aytu BioPharma (AYTU) Slips 1.7% to $2.36 as Biotech Volatility PersistsRisk Parity Rebalance - vinanet.vn
Aytu BioPharma (AYTU) Slips 1.7% to $2.36 as Biotech Volatility PersistsZigzag Correction - dars.gov.et
AYTU Q2 2026 Earnings: Narrow EPS Miss Slightly Wider Than Expected, Shares Rise 1.69%Earnings Expansion Phase - vinanet.vn
Aytu Biopharma Inc (AYTU) Stock News Today - TradingKey
Aytu BioPharma, Inc. (0A8M.L) valuation measures and financial statistics - Yahoo Finance Australia
Aytu Biopharma Inc (AYTU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CNSY Stock Price and Chart — NASDAQ:CNSY - tradingview.com
Aytu BioPharma (AYTU) Climbs 3.72% to $2.23 — Approaching Key ResistanceBreadth Thrust - vinanet.vn
Aytu BioScience Inc (0A8M) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Aytu Biopharma Inc (AYTU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aytu Biopharma Inc (AYTU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aytu BioPharma Market Sentiment - Benzinga España
Aytu Biopharma Inc (AYTU) Cash Flow - TradingKey
Aytu Biopharma Inc (AYTU) Balance Sheet - TradingKey
AYTU|Aytu Biopharma Inc|Price:2.107|Chg%:+0.046 - TradingKey
AYTU|Aytu Biopharma Inc|Price:2.160| - TradingKey
Aytu Biopharma Inc (AYTU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aytu Biopharma Inc (AYTU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aytu Biopharma Inc (AYTU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aytu Biopharma Inc (AYTU) Income Statement - TradingKey
AYTU Q2 2026 Earnings: EPS Misses Estimates by Nearly 2%, Stock Holds SteadyProfit Announcement - vinanet.vn
Aytu BioPharma, Inc. Revenue Breakdown – NASDAQ:AYTU - TradingView
AYTU Q2 2026 Earnings: EPS Slightly Misses Estimates with Minimal SurprisePerformance Review - vinanet.vn
AYTU Q2 2026 Earnings: EPS Misses Estimates Amid Challenging QuarterCore Business Growth - vinanet.vn
Aytu BioPharma (AYTU) Edges Higher as Stock Tests Key ResistanceOvernight Profile - vinanet.vn
AYTU Q2 2026 Earnings: EPS Misses Estimates Amid No Revenue; Stock Edges HigherCapex Guidance - vinanet.vn
AYTU Q2 2026 Earnings: EPS Misses Consensus, Stock Falls SlightlyRevenue Guidance Update - vinanet.vn
AYTU Q2 2026 Earnings: EPS Misses Estimates, Stock DeclinesNet Income Trends - vinanet.vn
New Strong Sell Stocks for July 16th - Yahoo Finance
AYTU Q2 2026 Earnings: EPS Misses Estimates, Shares Edge HigherPost-Earnings Drift - vinanet.vn
AYTU Q2 2026 Earnings: EPS Misses Estimates Amid Narrow Loss; Stock Edges HigherPost-Earnings Drift - vinanet.vn
Aytu BioPharma (AYTU) Edges Higher, Testing Key Resistance LevelsGap Fill Strategy - dars.gov.et
Aytu BioPharma (AYTU) Edges Higher, Testing Key Resistance LevelsBollinger Walk - DonanımHaber
Aytu BioPharma (AYTU) Edges Higher, Testing Key Resistance LevelsRVOL Breakout - dars.gov.et
AYTU Q2 2026 Earnings: EPS Miss Slightly Wider Than Expected; Stock Rises 2.74% Amid Strategic ReviewEarnings Beat Streak - dars.gov.et
AYTU Q2 2026 Earnings: EPS Misses Estimates Slightly, Stock Edges HigherNet Profit Margin - dars.gov.et
Aytu BioPharma Holds Steady Near $2.16 Amid Modest Gains – Key Levels in FocusFactor Valuation - DonanımHaber
Finanzdaten der Aytu Biopharma Inc-Aktie (AYTU)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.59%
2.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):